Literature DB >> 31075233

Gene polymorphism and risk of idiopathic membranous nephropathy.

Dongwei Liu1, Jiahui Zhang1, Yan Shi1, Zhangsuo Liu2.   

Abstract

Membranous nephropathy (MN) is the most common primary glomerular disease (PGD) in the world. Currently, MN still lacks specific diagnostic markers and effective treatment strategy. It is speculated that the occurrence of MN is mainly related to environmental and genetic factors. The pathological manifestations of MN patients are diverse, significant differences in response to treatment options, and more reports on young MN patients suggest the importance of genes in the pathogenesis and diagnosis of MN. We will propose a novel perspective on the important role of genes in the pathogenesis of MN baced on the latest research.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gene; Gene marker; HLA; MN; PLA2R; THSD7A

Mesh:

Substances:

Year:  2019        PMID: 31075233     DOI: 10.1016/j.lfs.2019.05.010

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  The telomerase gene polymorphisms, but not telomere length, increase susceptibility to primary glomerulonephritis/end stage renal diseases in females.

Authors:  Qing Sun; Junli Liu; Guanghui Cheng; Mingkai Dai; Jiaxi Liu; Zhenqiang Qi; Jingjie Zhao; Wei Li; Feng Kong; Gang Liu; Magnus Björkholm; Dawei Xu
Journal:  J Transl Med       Date:  2020-05-04       Impact factor: 5.531

Review 2.  Advances of the experimental models of idiopathic membranous nephropathy (Review).

Authors:  Han Xue Jiang; Zhendong Feng; Ze Bing Zhu; Chen Hui Xia; Wenting Zhang; Jing Guo; Bao-Li Liu; Yaoxian Wang; Yu Ning Liu; Wei Jing Liu
Journal:  Mol Med Rep       Date:  2020-03-09       Impact factor: 2.952

3.  Single-nucleotide polymorphism rs4664308 in PLA2R1 gene is associated with the risk of idiopathic membranous nephropathy: a meta-analysis.

Authors:  Masahiro Yoshikawa; Kensuke Asaba
Journal:  Sci Rep       Date:  2020-08-04       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.